42 related articles for article (PubMed ID: 16525495)
1. Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.
Zhang W; Choi J; Zeng W; Rogers SA; Alyea EP; Rheinwald JG; Canning CM; Brusic V; Sasada T; Reinherz EL; Ritz J; Soiffer RJ; Wu CJ
Clin Cancer Res; 2010 May; 16(10):2729-39. PubMed ID: 20460482
[TBL] [Abstract][Full Text] [Related]
2. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia.
Marijt WA; Heemskerk MH; Kloosterboer FM; Goulmy E; Kester MG; van der Hoorn MA; van Luxemburg-Heys SA; Hoogeboom M; Mutis T; Drijfhout JW; van Rood JJ; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2742-7. PubMed ID: 12601144
[TBL] [Abstract][Full Text] [Related]
3. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.
Chapuis AG; Ragnarsson GB; Nguyen HN; Chaney CN; Pufnock JS; Schmitt TM; Duerkopp N; Roberts IM; Pogosov GL; Ho WY; Ochsenreither S; Wölfl M; Bar M; Radich JP; Yee C; Greenberg PD
Sci Transl Med; 2013 Feb; 5(174):174ra27. PubMed ID: 23447018
[TBL] [Abstract][Full Text] [Related]
4. Propagation of cytotoxic effectors from chronic myeloid leukemia patients and cloning of cytotoxic T cells.
Somasundaram R; Advani SH; Gangal SG
Cancer Immunol Immunother; 1988; 27(2):183-9. PubMed ID: 3262015
[TBL] [Abstract][Full Text] [Related]
5. Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation.
Beatty GL; Smith JS; Reshef R; Patel KP; Colligon TA; Vance BA; Frey NV; Johnson FB; Porter DL; Vonderheide RH
Clin Cancer Res; 2009 Aug; 15(15):4944-53. PubMed ID: 19602548
[TBL] [Abstract][Full Text] [Related]
6. IL-21-treated naive CD45RA+ CD8+ T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype.
Albrecht J; Frey M; Teschner D; Carbol A; Theobald M; Herr W; Distler E
Cancer Immunol Immunother; 2011 Feb; 60(2):235-48. PubMed ID: 21046101
[TBL] [Abstract][Full Text] [Related]
7. In vitro generation of effector cells cytotoxic to autologous targets from chronic myeloid leukemia patients in remission.
Somasundaram R; Rao SG; Advani SH; Gangal SG
Cancer Immunol Immunother; 1988; 27(2):177-82. PubMed ID: 3262014
[TBL] [Abstract][Full Text] [Related]
8. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.
Molldrem JJ; Lee PP; Kant S; Wieder E; Jiang W; Lu S; Wang C; Davis MM
J Clin Invest; 2003 Mar; 111(5):639-47. PubMed ID: 12618518
[TBL] [Abstract][Full Text] [Related]
9. Coordinated Immune Cell Networks in the Bone Marrow Microenvironment Define the Graft versus Leukemia Response with Adoptive Cellular Therapy.
Maurer K; Park CY; Mani S; Borji M; Penter L; Jin Y; Zhang JY; Shin C; Brenner JR; Southard J; Krishna S; Lu W; Lyu H; Abbondanza D; Mangum C; Olsen LR; Neuberg DS; Bachireddy P; Farhi SL; Li S; Livak KJ; Ritz J; Soiffer RJ; Wu CJ; Azizi E
bioRxiv; 2024 Feb; ():. PubMed ID: 38405900
[TBL] [Abstract][Full Text] [Related]
10. Tumor vaccines and beyond.
Melenhorst JJ; Barrett AJ
Cytotherapy; 2011 Jan; 13(1):8-18. PubMed ID: 21067312
[TBL] [Abstract][Full Text] [Related]
11. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Porter DL; Alyea EP; Antin JH; DeLima M; Estey E; Falkenburg JH; Hardy N; Kroeger N; Leis J; Levine J; Maloney DG; Peggs K; Rowe JM; Wayne AS; Giralt S; Bishop MR; van Besien K
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1467-503. PubMed ID: 20699125
[TBL] [Abstract][Full Text] [Related]
12. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
Yong AS; Keyvanfar K; Hensel N; Eniafe R; Savani BN; Berg M; Lundqvist A; Adams S; Sloand EM; Goldman JM; Childs R; Barrett AJ
Blood; 2009 Jan; 113(4):875-82. PubMed ID: 18922853
[TBL] [Abstract][Full Text] [Related]
13. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
14. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells.
Kloosterboer FM; van Luxemburg-Heijs SA; van Soest RA; Barbui AM; van Egmond HM; Strijbosch MP; Kester MG; Marijt WA; Goulmy E; Willemze R; Falkenburg JH
Leukemia; 2004 Apr; 18(4):798-808. PubMed ID: 14973499
[TBL] [Abstract][Full Text] [Related]
15. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.
Faber LM; van der Hoeven J; Goulmy E; Hooftman-den Otter AL; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
J Clin Invest; 1995 Aug; 96(2):877-83. PubMed ID: 7635982
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
18. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells.
von dem Borne PA; van Luxemburg-Heijs SA; Heemskerk MH; Jedema I; Mulder A; Willemze R; Falkenburg JH
Leukemia; 2006 Jun; 20(6):1040-6. PubMed ID: 16525495
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
